Valeant Pharmaceuticals To Buy Aton For $318 Mil.; Bolsters U.S. Specialty Business
Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.
Acquisition is expected to buffer sales that will be lost when Valeant's epilepsy drug Diastat faces generic competition later this year.